ST Jiangsu Wuzhong: Lincomycin Hydrochloride Injection passes the consistency evaluation of generic drugs
ST SuWu announced that its wholly-owned subsidiary Suzhou Pharmaceutical Factory's Lincomycin Hydrochloride Injection has passed the consistency evaluation of generic drugs by the National Medical Products Administration. This approval will help enhance the market competitiveness of the drug and have a positive impact on its market sales. According to the policy, drugs that meet the consistency evaluation will receive support in terms of medical insurance payments, and medical institutions should prioritize procurement
According to the announcement from *ST Jiangsu Wuzhong (600200.SH), its wholly-owned subsidiary Jiangsu Wuzhong Pharmaceutical Group Co., Ltd. has recently received the "Drug Supplement Application Approval Notice" (Notice No.: 2025B04321) issued by the National Medical Products Administration regarding "Lincosamide Hydrochloride Injection." This drug has passed the consistency evaluation of generic drug quality and efficacy.
According to relevant national policy regulations, for drug varieties that have passed the consistency evaluation of generic drugs, appropriate support will be provided in terms of medical insurance payments, and medical institutions should prioritize procurement and clinical selection. If there are more than three manufacturers of the same drug variety that have passed the consistency evaluation of generic drugs, varieties that have not passed the consistency evaluation will no longer be selected in centralized drug procurement and other aspects. The company's Lincosamide Hydrochloride Injection has passed the consistency evaluation of generic drugs, which is beneficial for enhancing the market competitiveness of this drug and will have a positive impact on its market sales
